Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066270 | 0.90 | PDE10A (0.37) | PDE10APDCD1CD274AHR | |
| SCHEMBL2067920 | 0.86 | PDE10A (0.34) | PDE10APDCD1CD274AHRDRD2 | |
| SCHEMBL2066636 | 0.84 | PDE10A (0.40) | PDE10APDCD1CD274MCHR1DRD2 | |
| SCHEMBL2067442 | 0.81 | PDE10A (0.39) | PDE10APDCD1CD274MCHR1DRD2 | |
| SCHEMBL2068243 | 0.81 | PDE10A (0.53) | PDE10APDCD1CD274AHRDYRK1A | |
| SCHEMBL2066211 | 0.80 | PDE10A (0.38) | PDE10APDCD1CD274AHRCYP19A1 | |
| SCHEMBL2066059 | 0.80 | PDE10A (0.54) | PDE10APDCD1CD274AHRDRD2 | |
| SCHEMBL2065987 | 0.80 | PDE10A (0.58) | PDE10APDCD1CD274MCHR1AHR | |
| SCHEMBL2066173 | 0.79 | PDE10A (0.34) | PDE10APDCD1CD274AHRDRD2 | |
| SCHEMBL2066057 | 0.78 | PDE10A (0.36) | PDE10APDCD1CD274DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148524-B2 | Process for producing sulfonyl chloride compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| EP-1932846-B1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-20090247748-A1 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-1932846-A1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247748-A1 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SALL4, CLCN2, CLIC1 | PDE10A 3486/4885PDCD1 4007/4885CD274 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.